Plain-English translation of NCT07408505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called (a specially formulated version of an appetite-stimulating drug) combined with standard chemotherapy for people with advanced pancreatic cancer who are experiencing significant weight loss and loss of appetite. The medication uses nanotechnology to be absorbed better in the body, even when patients don't eat much. Researchers want to see if this treatment helps patients eat better, maintain their weight, and tolerate their chemotherapy more successfully.
Many people with advanced pancreatic cancer experience severe weight loss, muscle wasting, and poor appetite—even when they're getting chemotherapy. This combination of problems can make chemotherapy harder to tolerate and may worsen outcomes. While this medication is already recommended by doctors for appetite loss in cancer patients, researchers don't yet have strong evidence about the best way to use it alongside modern chemotherapy treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups: one group receives the new medication plus standard chemotherapy, while the other group receives chemotherapy alone. If assigned to the medication group, you would take 5 mL of the liquid medication by mouth once daily for up to 12 weeks, starting the same day your chemotherapy begins. You will have regular visits for blood tests, weight checks, appetite assessments, and scans to see how well the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China